All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 EGFR mutation Ex19del EGFR mutation L858R Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES previous systemic treatment (%) previous systemic treatment NO (%) smoker (current or former) smoker (never) stage I stage II stage IIIa
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lung cancer : non small cell (NSCLC), gene alteration target therapy vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results AURA3, 2017 0.87 [0.64; 1.18]
FLAURA, 2018 0.63 [0.45; 0.88]
0.75 [0.54 ; 1.02 ] AURA3, 2017, FLAURA, 2018 2 49% 975 moderate not evaluable progression or deaths (PFS)detailed results AURA3, 2017 0.30 [0.22; 0.40]
FLAURA, 2018 0.46 [0.37; 0.57]
0.38 [0.25 ; 0.57 ] AURA3, 2017, FLAURA, 2018 2 81% 975 low not evaluable DCRdetailed results AURA3, 2017 3.85 [2.18; 6.82]
FLAURA, 2018 2.92 [1.28; 6.68]
3.52 [2.20 ; 5.64 ] AURA3, 2017, FLAURA, 2018 2 0% 975 moderate not evaluable objective responses (ORR)detailed results AURA3, 2017 5.39 [3.45; 8.43]
FLAURA, 2018 1.27 [0.85; 1.90]
2.61 [0.63 ; 10.75 ] AURA3, 2017, FLAURA, 2018 2 95% 975 low not evaluable AE (any grade)detailed results AURA3, 2017 0.34 [0.04; 2.83]
FLAURA, 2018 1.01 [0.32; 3.16]
0.79 [0.29 ; 2.16 ] AURA3, 2017, FLAURA, 2018 2 0% 971 low not evaluable AE (grade 3-4)detailed results AURA3, 2017 0.31 [0.20; 0.48]
FLAURA, 2018 0.67 [0.47; 0.95]
0.46 [0.22 ; 0.98 ] AURA3, 2017, FLAURA, 2018 2 86% 971 low not evaluable AE leading to death (grade 5)detailed results AURA3, 2017 1.96 [0.22; 17.74]
FLAURA, 2018 0.59 [0.21; 1.64]
0.73 [0.29 ; 1.85 ] AURA3, 2017, FLAURA, 2018 2 0% 971 low not evaluable AE leading to treatment discontinuation (any grade)detailed results FLAURA, 2018 0.71 [0.45; 1.13]
0.71 [0.45 ; 1.13 ] FLAURA, 2018 1 0% 556 NA not evaluable SAE (any grade)detailed results FLAURA, 2018 0.81 [0.55; 1.20]
0.81 [0.55 ; 1.20 ] FLAURA, 2018 1 0% 556 NA not evaluable TRAE (any grade)detailed results AURA3, 2017 0.60 [0.32; 1.11]
FLAURA, 2018 0.42 [0.29; 0.60]
0.46 [0.34 ; 0.63 ] AURA3, 2017, FLAURA, 2018 2 0% 971 low not evaluable TRAE (grade 3-4)detailed results AURA3, 2017 0.12 [0.06; 0.22]
0.12 [0.06 ; 0.22 ] AURA3, 2017 1 0% 415 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-29 10:49 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 1413,435,434,1514,1515,474,1513,1390,714,423,424,425,562,426,1472,1400,1396,1468,431,1392,1391,1415,1416,1417,1493,1397,1383,1399,1426,1398,1387,1106,1108,1107,1393,1394,1402,1388,1389,1386,1384,1522,1385,1512,1511,1454
